Who
George A. Scangos
Director
Company insider
Files Form 4 as: Director, Voyager Therapeutics; Director, Agilent Technologies; President and CEO, Vir Biotechnology; President & CEO, Exelixis; Chief Executive Officer, Biogen; Director, Anadys Pharmaceuticals.
In numbers
- Trades disclosed
- 2,006
- Buys
- 3
- Sells
- 195
- Bought
- $155K
- Sold
- $59.5M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 5 Jan 2006
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $118K1,057 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $118K1,057 at $111.75 | filing |
| 3 Jun 2025filed 4 Jun 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $220K1,819 at $121.18 | filing |
| 24 Feb 2025filed 25 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $95K10,056 at $9.45 | filing |
| 18 Feb 2025filed 19 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $108K10,964 at $9.81 | filing |
| 23 Oct 2024filed 24 Oct 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —598,270 at $0.00 | filing |
| 23 Oct 2024filed 24 Oct 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —598,270 at $0.00 | filing |
| 23 Oct 2024filed 24 Oct 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —598,270 at $0.00 | filing |
| 23 Oct 2024filed 24 Oct 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code J | —598,270 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code G | $501K3,443 at $145.48 | filing |
| 29 May 2024filed 31 May 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code G | $501K3,443 at $145.48 | filing |
| 15 Mar 2024filed 19 Mar 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $247K1,678 at $147.48 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00VIR · tickerreport.com · 10 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026Exelixis v. MSN Shows the Reach of Earlier Genus PatentsEXEL · natlawreview.com · 7 Oct 2026
0 headlines in the last 90 days name George A. Scangos; 8 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.